Pediatric allergy medications: review of currently available formulations

Glenis Scadding1

  • 1Royal National Throat Nose & Ear Hospital, London WC1X 8DA, UK. g.scadding@ucl.ac.uk

Insights

Pediatric allergic rhinitis (AR) treatments face challenges in administration and formulation. New sugar-free and dye-free options are emerging to improve safety and convenience for children with AR.

Area of Science:

  • Pediatric Allergy and Immunology
  • Pharmaceutical Sciences
  • Public Health

Background:

  • Allergic rhinitis (AR) impacts approximately 50% of the global pediatric population.
  • AR significantly impairs children's quality of life, affecting sleep, school attendance, and academic performance.

Purpose of the Study:

  • To review available medications for pediatric allergic rhinitis (AR).
  • To assess parental and healthcare professional attitudes towards pediatric AR medications.
  • To identify current recommendations and labeling requirements for pediatric AR treatments.

Main Methods:

  • Systematic review of guidelines from international organizations and governmental websites.
  • Medline search utilizing terms related to pediatric medication ingredients and prescribing habits.
  • Evaluation of traditional and novel formulations for pediatric AR treatment.

Main Results:

  • Increasing demand for safer, more convenient pediatric medicines, particularly sugar-free and dye-free options.
  • Availability of diverse formulations like granules, filmstrips, and fast-dissolving tablets for pediatric use.
  • Regulatory agencies recommend avoiding sugar in pediatric medicines.

Conclusions:

  • Limited well-designed trials exist for pediatric AR treatments.
  • Safety, tolerability, convenience, and acceptance are crucial for long-term AR management in children.
  • Potential for social response bias in parental and physician perceptions of medication ingredients.
Abstract

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin, heparin),...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Upper Respiratory Drugs: First and Second-Generation Antihistamines01:15

Upper Respiratory Drugs: First and Second-Generation Antihistamines

Antihistamines are a class of drugs widely used to alleviate the symptoms of allergies, such as sneezing, itching, and nasal congestion. They work by inhibiting the actions of histamine, which is released by immune cells in response to allergenic substances or tissue injuries.
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Allergic Reactions02:06

Allergic Reactions

Overview